Use of Erythropoiesis-Stimulating Agents in Patients With Anemia of Chronic Kidney Disease: Overcoming the Pharmacological and Pharmacoeconomic Limitations.

Slides:

Advertisements

Similar presentations

Clinical Pharmacology, Uses, and Adverse Reactions of Iodinated Contrast Agents: A Primer for the Non-radiologist Jeffrey J. Pasternak, MD, Eric E. Williamson,

Advertisements

My Treatment Approach to Hairy Cell Leukemia Rahul R. Naik, MD, Alan Saven, MD Mayo Clinic Proceedings Volume 87, Issue 1, Pages (January 2012) DOI:

Hypothesis: an erythropoietin honeymoon phase exists

Algorithm for management of anemia of CKD in adults

My Treatment Approach to Gout

Managing Cancer Pain: Basic Principles and Invasive Treatments

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Cidofovir Treatment of Progressive Multifocal Leukoencephalopathy in a Patient Receiving Highly Active Antiretroviral Therapy Raymund R. Razonable, MD,

J. Eric Ahlskog, PhD, MD Mayo Clinic Proceedings

Evaluation of Proteinuria

Jean L. Chan, MD, Martin J. Abrahamson, MD Mayo Clinic Proceedings

New options for the anemia of chronic kidney disease

William L. Lanier, MD Mayo Clinic Proceedings

Diagnosis and Management of Chronic Kidney Disease

American Journal of Kidney Diseases

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Mitchell H. Rosner, W. Kline Bolton Kidney International

Douglas S. Fuller, MS, Ronald L. Pisoni, PhD, MS, Brian A

A Comparison of Long- and Short-Acting Opioids for the Treatment of Chronic Noncancer Pain: Tailoring Therapy to Meet Patient Needs Charles E. Argoff,

Thinking Beyond New Clinical Guidelines: Update in Hypertension

My Treatment Approach to Gout

Michele A. Hanson, M.D., Daniel A. Dumesic, M.D.

Peripheral Arterial Disease: Diagnosis and Management

Volume 88, Issue 5, Pages (November 2015)

Current Concepts in Anticoagulant Therapy

Volume 90, Issue 5, Pages (November 2016)

George Dailey, MD Mayo Clinic Proceedings

Tait D. Shanafelt, MD, Timothy G. Call, MD Mayo Clinic Proceedings

Gestational Trophoblastic Disease

ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target Szu-Chun Hung, Der-Cherng Tarng Kidney International

Julia A. Files, MD, Marcia G. Ko, MD, Sandhya Pruthi, MD

Palliative Care and Hospice Programs

Topical Analgesics in the Management of Acute and Chronic Pain

Gerry H. Tan, M.D., Roger L. Nelson, M.D. Mayo Clinic Proceedings

Oxygen-Exacerbated Bleomycin Pulmonary Toxicity

Focusing on Health Literacy Might Help Us Cross the Quality Chasm

Volume 70, Pages S21-S25 (December 2006)

Chapter 4: Red cell transfusion to treat anemia in CKD

The DOPPS Practice Monitor for US Dialysis Care: Update on Trends in Anemia Management 2 Years Into the Bundle Douglas S. Fuller, MS, Ronald L. Pisoni,

Ayalew Tefferi, MD Mayo Clinic Proceedings

Daniel M. Musher, MD Mayo Clinic Proceedings

The Red Scalp Sign Mayo Clinic Proceedings

MIGUEL A. VALDOVINOS, M. D. , MICHAEL CAMILLERI, M. D. , BRUCE R

Toxic Effects Associated With Consumption of Zinc

Current, Emerging, and Anticipated Therapies for Sickle Cell Disease

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

Quiz Page July 2012 American Journal of Kidney Diseases

74-Year-Old Woman With Dyspnea on Exertion and Anemia

A Decade After the KDOQI CKD Guidelines: A Perspective From Mexico

Best Practices for Patients With Chronic Migraine

Classic Hodgkin Lymphoma

Günter Weiss, Florian Kronenberg Kidney International

Francesco Locatelli, Lucia Del Vecchio Kidney International

Renal Pyelocalyceal Squamous Cell Carcinoma

Osteoporosis Associated With Megestrol Acetate

Simon M. Glynn, MD, Sean J. Pittock, MD, Steven A. Vernino, MD, PhD

Hepatocellular Carcinoma

Methylphenidate: Its Pharmacology and Uses

Medical Treatment of Overactive Bladder: In Response

Mantle Cell Involvement of the Spleen

Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease Dean G. Karalis, MD Mayo Clinic Proceedings

Squamous Cell Carcinoma of the Tongue

Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? Elias Jabbour, MD, Jorge E. Cortes,

Preoperative Smoking Cessation: The Role of the Primary Care Provider

Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation A.K. Singh, D.W. Coyne,

Guru Sonpavde, MD, Teresa G. Hayes, MD Mayo Clinic Proceedings

Clomiphene-Induced Severe Hypertriglyceridemia and Pancreatitis

Managing Cancer Pain: Basic Principles and Invasive Treatments

Acute and Chronic Seizures in Patients Older Than 60 Years

Mayo Clinic Proceedings 2012: “A New Era in Journal Stewardship”

Presentation transcript:

Use of Erythropoiesis-Stimulating Agents in Patients With Anemia of Chronic Kidney Disease: Overcoming the Pharmacological and Pharmacoeconomic Limitations of Existing Therapies Jay B. Wish, MD, Daniel W. Coyne, MD Mayo Clinic Proceedings Volume 82, Issue 11, Pages 1371-1380 (November 2007) DOI: 10.4065/82.11.1371 Copyright © 2007 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 1 Initiation of anemia management in patients with CKD. CBC = complete blood cell count; CKD = chronic kidney disease; ESA = erythropoiesis-stimulating agent; Hb = hemoglobin; RBC = red blood cell. Mayo Clinic Proceedings 2007 82, 1371-1380DOI: (10.4065/82.11.1371) Copyright © 2007 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 2 Recommended ESA treatment in patients with CKD. CKD = chronic kidney disease; ESA = erythropoiesis-stimulating agent; GI= gastrointestinal; Hb= hemoglobin; IV = intravenous; SC = subcutaneous. Mayo Clinic Proceedings 2007 82, 1371-1380DOI: (10.4065/82.11.1371) Copyright © 2007 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 3 Recommended iron therapy for patients with CKD who are receiving erythropoiesis-stimulating agents. SI conversion factor, to convert serum ferritin level to pmol, multiply by 2.247. CHr = reticulocyte hemoglobin content; CKD = chronic kidney disease; IV = intravenous. Mayo Clinic Proceedings 2007 82, 1371-1380DOI: (10.4065/82.11.1371) Copyright © 2007 Mayo Foundation for Medical Education and Research Terms and Conditions